Kodiak Sciences
Präsenz
Kodiak Sciences ist einer der ...
Kodiak Sciences ist ein Unternehmen, das unter dem Börsenticker KOD (US) gelistet ist.
Führungskräfte
Siehe das Organigramm mit seine 20 wichtigsten Führungskräfte
Die meist gesuchten Biographien bei Kodiak Sciences
- Victor Perlroth, Chairman and Chief Executive Officer
- Taiyin Yang, Director
- Charles Bancroft, Director
Letzte Veränderungen der Führungskräfte auf Kodiak Sciences
- Jason Ehrlich, Chief Medical Officer and Chief Development Officer, wird das Unternehmen am 25 Aug.. 2023 verlassen (Nachrichten veröffentlicht am 18, August 2023).
Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von Kodiak Sciences nachzuverfolgen.
Biotechnologie
Kodiak Sciences hat 2.276 Konkurrenten , einschließlich Eurofins (Luxemburg), Lonza (Schweiz) und Adaptive Phage Therapeutics (USA).
Popular M&A news in Biotechnologie
- Histogen has filed for bankruptcy protection (veröffentlicht am 19, April 2024).
- Bruker has announced the acquisition of NanoString Technologies (veröffentlicht am 18, April 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (veröffentlicht am 16, April 2024).
Andere vorgeschlagene Kontakte der Biotechnologie branche
Nachrichten
Neueste Pressemitteilungen nach Kodiak Sciences
- Kodiak Sciences Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion | Kodiak Sciences Inc.
- Kodiak Sciences to Present at Upcoming Conferences | Kodiak Sciences Inc.
- Kodiak Sciences Announces Second Quarter 2020 Financial Results and Recent Business Highlights | Kodiak Sciences Inc.
- Lonza's Ibex Dedicate to Support the Commercial Manufacture of Kodiak’s KSI-301 - an Antibody Biopolymer Conjugate for Retinal Diseases | Kodiak Sciences Inc.
- Kodiak Sciences to Host R&D Webcast to Review Recent Data from the Ongoing Phase 1b Study of KSI-301 and Highlight KSI-301 Clinical Development Progress | Kodiak Sciences Inc.
- Kodiak Sciences Announces New Longer-Term Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Society of Retin
- Kodiak Sciences Announces Upcoming Presentation of KSI-301 Clinical Study Data at American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting and R&D Webinar | Kodiak Sciences Inc.
- Kodiak Sciences to Present at Upcoming Conferences | Kodiak Sciences Inc.
- Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference | Kodiak Sciences Inc.
- Kodiak Sciences Announces First Quarter 2020 Financial Results and Recent Business Highlights | Kodiak Sciences Inc.
- View more press releases Close
Social media about Kodiak Sciences
- Kodiak Sciences auf Wikipedia, Google News & Yahoo Finance
- Kodiak Sciences auf LinkedIn, Twitter & YouTube
In Kontakt kommen
Jetzt seine Führungskräfte, darunter auch Victor Perlroth, per E-Mail kontaktieren. 
Kodiak Sciences unter +1 650... anrufen
